人群糖尿病心肌病二级预防生物标志物的筛选及代谢机制研究

Diabetic cardiomyopathy (DCM) is the main complications and heavy disease burden of patient with diabetes mellitus and has been an important public health issue for its high prevalence and mortality rate in the world. The insidious onset and slow progression of clinical symptoms result in losing the best time for the the prevention and treatment of DCM. Therefore, for the sake of clear diagnosing early-stage, instantaneous intervening and curing, and improving the clinical cure rates, researching the best biomarkers of early-stage DCM and the corresponding metabolic mechanism is extremely important.This topic is planned to exploit UPLC/Q-TOF-MS for investigating the types and the contents of metabolites in blood and urine between DCM patients and controls. Then their metabolic fingerprinting in blood and urine and the corresponding biological significance are described by multivariate statistical analysis; Biomarkers for distinguishing the case group and the controls will be screened, identified, and used to understand the metabolic patterns, discuss the potential roles in diagnoses, prognoses, and further clarify the pathological mechanism of DCM. On the other hand, replenishing and proving the obtained results through designing a series of animal experiments, disclosing the metabolic mechanism of relative biomarkers, discussing the pathogeny based on metabonomics.

糖尿病心肌病（Diabetic cardiomyopathy，DCM）是糖尿病患者主要并发症，给糖尿病患者带来沉重的疾病负担，其高患病率、高死亡率已使其成为全球重要公共卫生问题。DCM 起病隐匿，进展缓慢，当出现明显临床症状时，较好的预防和治疗时机已错失，因此筛选DCM的二级预防生物标志物并研究其代谢机制对于早期明确诊断，及时干预和治疗以及提高临床治愈率具有重要意义。本课题拟利用超高效液相色谱串联四级杆飞行时间质谱（UPLC/Q-TOF-MS) 检测技术，研究糖尿病心肌病患者及对照人群血、尿中代谢物的种类、含量及其变化，筛选并确定能够区别病例与对照的有意义的生物标志物，从而了解DCM的代谢模式，并探讨其潜在的DCM诊断和预测作用。另一方面，通过动物实验研究，补充和验证人群研究结果，揭示相关生物标志物的代谢机制，以从代谢组学角度探讨DCM的病因，为DCM的防治提供新思路。

糖尿病心肌病（Diabetic cardiomyopathy，DCM）是糖尿病患者主要并发症，给糖尿病患者带来沉重的疾病负担，其高患病率、高死亡率已使其成为全球重要公共卫生问题。DCM 起病隐匿，进展缓慢，当出现明显临床症状时，较好的预防和治疗时机已错失，因此筛选DCM的二级预防生物标志物并研究其代谢机制对于早期明确诊断，及时干预和治疗以及提高临床治愈率具有重要意义。本课题利用超高效液相色谱串联四级杆飞行时间质谱（UPLC/Q-TOF-MS) 检测技术，研究糖尿病心肌病患者及对照人群血、尿中代谢物的种类、含量及其变化，筛选并确定能够区别病例与对照的有意义的生物标志物，从而了解DCM的代谢模式，并探讨其潜在的DCM诊断和预测作用。另一方面，通过动物实验研究，补充和验证人群研究结果，揭示相关生物标志物的代谢机制，以从代谢组学角度探讨DCM的病因，为DCM的防治提供新思路。